Results from Phase 2b part of inhaled imatinib trial due in June
The Phase 2b portion of the IMPAHCT clinical trial, which is testing multiple doses of the inhaled imatinib formulation AV-101 against a placebo in adults with pulmonary arterial hypertension (PAH), has finished enrollment. Top-line results are expected in June 2024, according to AV-101’s developer, Aerovate Therapeutics. “The completion…